Browse studies

Find your next paid study

127 recruiting studies matching your filters

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Low-Dose Post-Transplant Cyclophosphamide for Prophylaxis of Graft-versus-Host Disease in Hematological Malignancies

This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophyla…

Graft-versus-Host Disease (GVHD)Hematologic MalignanciesAllogeneic Stem Cell Transplantation

Estimated

~$10 – $6,250

Milton S. Hershey Medical CenterNCT06926595

Observational

Reducing Persistent Fatigue Following Hematopoietic Stem Cell Transplantation

The purpose of this study is to assess whether a cognitive-behavioral therapy (CBT) for fatigue intervention is acceptable, feasible, and effective at managing…

Hematologic CancerHematologic Malignancy

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT05715047

Phase 2

Optimized CBT for Pts With High-risk Hematologic Malignancies Who Have Relapsed After First ASCT

The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control hig…

Hematologic Malignancies

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06807606

Phase 1

A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies

This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.

Hematologic Malignancies

Estimated

~$10 – $8,750

Ascentage Pharma Group Inc.NCT03537482

Phase 1

Phase 1/1b Study of T-allo10 Infusion After HLA-Partially Matched Related or Unrelated TCR αβ+ T-cell/ CD19+ B-cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (αβ Depleted-HSCT) in Children and Young Adults Affected by Hematologic Malignancies

The purpose of this study is to determine the safety of a cell therapy, T-allo10, after αβdepleted-HSCT in the hopes that it will boost the adaptive immune rec…

Hematologic Diseases

Estimated

~$10 – $7,500

Porteus, Matthew, MDNCT04640987

Observational

Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation

Primary PC - or training HCT clinicians to deliver PC domains as part of routine practice - is an alternative model of supportive care. We have developed Senti…

Hematopoietic Cell TransplantHematologic Malignancy

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT06676852

Implementation of Comprehensive Molecular Profiling and Deep Clinical Annotation of Electronic Health Records in Participants Diagnosed With or at Risk of Developing Cancer (ASAP Study)

The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-bas…

CancerCancer DiagnosisEarly Detection of Cancer+9 more

Estimated

~$10 – $750

Avera McKennan Hospital & University Health CenterNCT05142033